Organisation paid for research Program year 2025 Source: CMS Open Payments

Sierra Eye Associates

Neither a doctor nor a teaching hospital

Research payments

$27,989,563

1,727 payments

Through program year 2025, Sierra Eye Associates is reported as receiving $27,989,563 in research payments, across 1,727 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$7,236,204	634
2024	Research	$3,084,706	345
2023	Research	$2,020,995	219
2022	Research	$1,184,235	80
2021	Research	$6,127,888	247
2020	Research	$5,903,842	137
2019	Research	$2,431,694	65

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $13,191,529 771 payments
Ocular Therapeutix, Inc. $7,345,762 362 payments
Novartis Pharmaceuticals Corporation $3,259,179 25 payments
Roche TCRC, Inc. $2,222,388 171 payments
Kyowa Kirin, Inc. $1,165,611 326 payments
Alexion Pharmaceuticals, Inc. $295,021 3 payments
Sanofi US Services Inc. $269,477 27 payments
Astellas Pharma Global Development $225,514 37 payments
Allergan Inc. $15,082 5 payments

Studies the money was for Research payments · program years 2019–2025

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $6,057,660 306 payments
A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $2,530,416 4 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $2,194,456 55 payments
Va2 Phiii $2,113,351 38 payments
Port Delivery System for Ranibizumab $1,645,245 48 payments
Phase 2 Study to Investigate Ro7200220 in Diabetic MacUlar Edema $1,443,080 53 payments
Iamd Observational Study $1,364,188 185 payments
Va2 Phiii Yosemite $1,296,014 34 payments
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema $969,820 227 payments
Port Delivery System of Ranizibumab Extension Study $867,390 40 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.